Erlotinib
CURRENT LOCATION:
HOMEKey projects》Erlotinib

Erlotinib

Project NameErlotinib 

Registration Classification:3+6

Formulations and specifications Tablets: 25mg, 100mg, 150mg 

IndicationsFor locally advanced or metastatic non-small cell lung cancer (NSCLC) after at least one previously failure chemotherapy .

Original Research CompanyRoche 

Progress Pharmaceutical Research in progress 

Category :Cancer drug 

Links:

地址:北京市丰台区造甲街南里5号4A楼2层
电话:010-63716441 63717341 传真:010-63728443
COPYRIGHT (C) 2014 Beijing Mega Pharmaceutical Science and Technology Co.,ltd. ALL RIGHTS RESERVED
版权所有 北京满格医药科技有限公司 京ICP备12000952号